{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:40:20Z","timestamp":1794465620613,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health"},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-052365"],"award-info":[{"award-number":["INV-052365"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-061041"],"award-info":[{"award-number":["INV-061041"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CIS43LS is a long-acting monoclonal antibody specific for the\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    circumsporozoite protein expressed on sporozoites. We previously reported that CIS43LS is protective against\n                    <jats:italic>P.<\/jats:italic>\n                    \u2009\n                    <jats:italic>falciparum<\/jats:italic>\n                    infection as detected by thick blood smear (TBS; primary endpoint) in a phase\u20092 double-blind randomized trial involving 330 healthy Malian adults receiving placebo or a single intravenous infusion of 10\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    or 40\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    of CIS43LS (1:1:1). At enrollment, all participants received artemether\u2013lumefantrine to clear possible\n                    <jats:italic>P.<\/jats:italic>\n                    \u2009\n                    <jats:italic>falciparum<\/jats:italic>\n                    infection. Although TBS examination is the standard assay to assess efficacy in malaria vaccines trials in endemic areas, it has poor analytical sensitivity; therefore, it remained unknown whether CIS43LS had achieved sterile protection against infection. Here we report the prespecified secondary efficacy endpoint that used a\n                    <jats:italic>Plasmodium<\/jats:italic>\n                    18S rRNA quantitative reverse transcription\u2013PCR (qRT\u2013PCR) assay that is ~2,000-fold more sensitive than TBS. We analyzed 5,015 dried blood spots collected before CIS43LS or placebo administration and biweekly thereafter over a 6-month malaria season. At 6\u2009months, efficacy of CIS43LS against qRT\u2013PCR-detected infection assessed in a time-to-event analysis was 87.4% for 40\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    (adjusted 95% confidence interval (CI), 79.5\u201392.3;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and 77.0% for 10\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    (adjusted 95% CI, 65.0\u201384.0;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) versus placebo. A post hoc analysis with a gametocyte mRNA-specific qRT\u2013PCR assay showed 6-month efficacy against gametocytemia of 87.7% for 40\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    (adjusted 95% CI, 75.6\u201393.8;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and 73.0% for 10\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    (adjusted 95% CI, 54.0\u201384.0;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), versus placebo. These data indicate that a single dose of anti-sporozoite monoclonal antibodies can achieve durable, sterile protection against\n                    <jats:italic>P.<\/jats:italic>\n                    \u2009\n                    <jats:italic>falciparum<\/jats:italic>\n                    infection, underscoring their potential to reduce malaria disease burden and transmission. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04329104\" ext-link-type=\"uri\">NCT04329104<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-03739-y","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:01:53Z","timestamp":1748926913000},"page":"2682-2690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5697-0442","authenticated-orcid":false,"given":"Jeff","family":"Skinner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassoum","family":"Kayentao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aissata","family":"Ongoiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-6094","authenticated-orcid":false,"given":"Sara A.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadou","family":"Niangaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-3332","authenticated-orcid":false,"given":"Hamidou","family":"Cisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiatou","family":"Doumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Doumtabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdrahamane","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"Seilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chavtur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weston","family":"Staubus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamadi","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adama","family":"Djiguiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Keita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adama","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2019Bouye","family":"Doucoure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Keita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djelika","family":"Diarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Sylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dramane","family":"Diakite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Konate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriman","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amatigu\u00e9","family":"Z\u00e9guim\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amagana","family":"Dolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1665-9323","authenticated-orcid":false,"given":"Daniel E.","family":"Neafsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-0131","authenticated-orcid":false,"given":"Sean C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boubacar","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-0849","authenticated-orcid":false,"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-0412","authenticated-orcid":false,"given":"Peter D.","family":"Crompton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"3739_CR1","unstructured":"World Malaria Report 2024 (World Health Organization, 2024); www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"3739_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1146\/annurev.micro.091208.073403","volume":"63","author":"AS Aly","year":"2009","unstructured":"Aly, A. S., Vaughan, A. M. & Kappe, S. H. Malaria parasite development in the mosquito and infection of the mammalian host. Annu. Rev. Microbiol. 63, 195\u2013221 (2009).","journal-title":"Annu. Rev. Microbiol."},{"key":"3739_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/j.1462-5822.2006.00861.x","volume":"9","author":"LM Yamauchi","year":"2007","unstructured":"Yamauchi, L. M., Coppi, A., Snounou, G. & Sinnis, P. Plasmodium sporozoites trickle out of the injection site. Cell Microbiol. 9, 1215\u20131222 (2007).","journal-title":"Cell Microbiol."},{"key":"3739_CR4","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1084\/jem.151.6.1504","volume":"151","author":"P Potocnjak","year":"1980","unstructured":"Potocnjak, P., Yoshida, N., Nussenzweig, R. S. & Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151, 1504\u20131513 (1980).","journal-title":"J. Exp. Med."},{"key":"3739_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.6204383","volume":"225","author":"JB Dame","year":"1984","unstructured":"Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593\u2013599 (1984).","journal-title":"Science"},{"key":"3739_CR6","unstructured":"World Health Organization. Malaria vaccines: WHO position paper. Wkly Epidemiol. Rec. 99, 225\u2013248 (2024)."},{"key":"3739_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership.","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"3739_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"3739_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrmicro3364","volume":"12","author":"T Bousema","year":"2014","unstructured":"Bousema, T., Okell, L., Felger, I. & Drakeley, C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat. Rev. Microbiol. 12, 833\u2013840 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"3739_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1473-3099(24)00179-8","volume":"24","author":"M Juraska","year":"2024","unstructured":"Juraska, M. et al. Genotypic analysis of RTS,S\/AS01(E) malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. Lancet Infect. Dis. 24, 1025\u20131036 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3739_CR11","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(01)06957-4","volume":"358","author":"KA Bojang","year":"2001","unstructured":"Bojang, K. A. et al. Efficacy of RTS,S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927\u20131934 (2001).","journal-title":"Lancet"},{"key":"3739_CR12","doi-asserted-by":"publisher","first-page":"e6465","DOI":"10.1371\/journal.pone.0006465","volume":"4","author":"ME Polhemus","year":"2009","unstructured":"Polhemus, M. E. et al. Evaluation of RTS,S\/AS02A and RTS,S\/AS01B in adults in a high malaria transmission area. PLoS ONE 4, e6465 (2009).","journal-title":"PLoS ONE"},{"key":"3739_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"3739_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski, M. R. et al. A monoclonal antibody for malaria prevention. N. Engl. J. Med. 385, 803\u2013814 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3739_CR15","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41590-024-01938-2","volume":"25","author":"LT Wang","year":"2024","unstructured":"Wang, L. T., Idris, A. H., Kisalu, N. K., Crompton, P. D. & Seder, R. A. Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention. Nat. Immunol. 25, 1530\u20131545 (2024).","journal-title":"Nat. Immunol."},{"key":"3739_CR16","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","volume":"387","author":"K Kayentao","year":"2022","unstructured":"Kayentao, K. et al. Safety and efficacy of a monoclonal antibody against malaria in Mali. N. Engl. J. Med. 387, 1833\u20131842 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3739_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-5-104","volume":"5","author":"P Bejon","year":"2006","unstructured":"Bejon, P. et al. Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malar. J. 5, 104 (2006).","journal-title":"Malar. J."},{"key":"3739_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4269\/ajtmh.2007.77.119","volume":"77","author":"C Wongsrichanalai","year":"2007","unstructured":"Wongsrichanalai, C., Barcus, M. J., Muth, S., Sutamihardja, A. & Wernsdorfer, W. H. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). Am. J. Trop. Med. Hyg. 77, 119\u2013127 (2007).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3739_CR19","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.4269\/ajtmh.19-0094","volume":"100","author":"AM Seilie","year":"2019","unstructured":"Seilie, A. M. et al. Beyond blood smears: qualification of plasmodium 18S rRNA as a biomarker for controlled human malaria infections. Am. J. Trop. Med. Hyg. 100, 1466\u20131476 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3739_CR20","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/S2666-5247(23)00262-8","volume":"5","author":"DEB Hergott","year":"2024","unstructured":"Hergott, D. E. B. et al. Assessing the daily natural history of asymptomatic Plasmodium infections in adults and older children in Katakwi, Uganda: a longitudinal cohort study. Lancet Microbe 5, e72\u2013e80 (2024).","journal-title":"Lancet Microbe"},{"key":"3739_CR21","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.4269\/ajtmh.21-1226","volume":"106","author":"J Matsubara","year":"2022","unstructured":"Matsubara, J., Chang, M., Seilie, A. M. & Murphy, S. C. Flow cytometric sorting of infected erythrocytes demonstrates reliable detection of individual ring-stage Plasmodium falciparum parasites by plasmodium 18S rRNA reverse transcription polymerase chain reaction. Am. J. Trop. Med. Hyg. 106, 1653\u20131659 (2022).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3739_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1863-3","volume":"16","author":"AE Hanron","year":"2017","unstructured":"Hanron, A. E. et al. Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs. Malar. J. 16, 208 (2017).","journal-title":"Malar. J."},{"key":"3739_CR23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","volume":"390","author":"K Kayentao","year":"2024","unstructured":"Kayentao, K. et al. Subcutaneous administration of a monoclonal antibody to prevent malaria. N. Engl. J. Med. 390, 1549\u20131559 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3739_CR24","doi-asserted-by":"publisher","first-page":"ofad202","DOI":"10.1093\/ofid\/ofad202","volume":"10","author":"C Chavtur","year":"2023","unstructured":"Chavtur, C. et al. Plasmodium 18S ribosomal RNA biomarker clearance after Food and Drug Administration-approved antimalarial treatment in controlled human malaria infection trials. Open Forum Infect. Dis. 10, ofad202 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"3739_CR25","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/S1473-3099(21)00072-4","volume":"21","author":"C Andolina","year":"2021","unstructured":"Andolina, C. et al. Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. Lancet Infect. Dis. 21, 1568\u20131578 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"3739_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4269\/ajtmh.2007.76.470","volume":"76","author":"P Schneider","year":"2007","unstructured":"Schneider, P. et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am. J. Trop. Med. Hyg. 76, 470\u2013474 (2007).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3739_CR27","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1371\/journal.pmed.0020092","volume":"2","author":"CJ Sutherland","year":"2005","unstructured":"Sutherland, C. J. et al. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med. 2, e92 (2005).","journal-title":"PLoS Med."},{"key":"3739_CR28","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/infdis\/jit077","volume":"207","author":"P Sawa","year":"2013","unstructured":"Sawa, P. et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J. Infect. Dis. 207, 1637\u20131645 (2013).","journal-title":"J. Infect. Dis."},{"key":"3739_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S2666-5247(24)00023-5","volume":"5","author":"A Mahamar","year":"2024","unstructured":"Mahamar, A. et al. Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali. Lancet Microbe 5, 633\u2013644 (2024).","journal-title":"Lancet Microbe"},{"key":"3739_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41573-024-00933-4","volume":"23","author":"M Duffey","year":"2024","unstructured":"Duffey, M. et al. Combating antimicrobial resistance in malaria, HIV and tuberculosis. Nat. Rev. Drug Discov. 23, 461\u2013479 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3739_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/science.adp5137","volume":"385","author":"M Dhorda","year":"2024","unstructured":"Dhorda, M. et al. Artemisinin-resistant malaria in Africa demands urgent action. Science 385, 252\u2013254 (2024).","journal-title":"Science"},{"key":"3739_CR32","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.7326\/M22-1329","volume":"175","author":"EK McCreary","year":"2022","unstructured":"McCreary, E. K. et al. Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy: a cohort study. Ann. Intern. Med. 175, 1707\u20131715 (2022).","journal-title":"Ann. Intern. Med."},{"key":"3739_CR33","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/microorganisms11081953","volume":"11","author":"P Crispino","year":"2023","unstructured":"Crispino, P. et al. Use of monoclonal antibodies in pregnant women infected by COVID-19: a case series. Microorganisms 11, 1953 (2023).","journal-title":"Microorganisms"},{"key":"3739_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s15010-022-01829-4","volume":"51","author":"R Folkman","year":"2023","unstructured":"Folkman, R., Blennow, O., Tovatt, T., Pettersson, K. & Nowak, P. Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infection 51, 261\u2013263 (2023).","journal-title":"Infection"},{"key":"3739_CR35","doi-asserted-by":"publisher","first-page":"100673","DOI":"10.1016\/j.ajogmf.2022.100673","volume":"4","author":"NH Levey","year":"2022","unstructured":"Levey, N. H. et al. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic. Am. J. Obstet. Gynecol. MFM 4, 100673 (2022).","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"3739_CR36","doi-asserted-by":"publisher","first-page":"E1129","DOI":"10.1503\/cmaj.202391","volume":"193","author":"A Pham-Huy","year":"2021","unstructured":"Pham-Huy, A., Top, K. A., Constantinescu, C., Seow, C. H. & El-Chaar, D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 193, E1129\u2013E1136 (2021).","journal-title":"CMAJ"},{"key":"3739_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/tropicalmed7080152","volume":"7","author":"A Figueroa-Romero","year":"2022","unstructured":"Figueroa-Romero, A., Pons-Duran, C. & Gonzalez, R. Drugs for intermittent preventive treatment of malaria in pregnancy: current knowledge and way forward. Trop. Med. Infect. Dis. 7, 152 (2022).","journal-title":"Trop. Med. Infect. Dis."},{"key":"3739_CR38","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/S1473-3099(22)00428-5","volume":"22","author":"SC van der Boor","year":"2022","unstructured":"van der Boor, S. C. et al. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet Infect. Dis. 22, 1596\u20131605 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"3739_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/14760584.2021.1878028","volume":"20","author":"PE Duffy","year":"2021","unstructured":"Duffy, P. E. Transmission-blocking vaccines: harnessing herd immunity for malaria elimination. Expert Rev. Vaccines 20, 185\u2013198 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"3739_CR40","doi-asserted-by":"publisher","unstructured":"Copeland, N. K. et al. Phase 2b clinical study evaluating efficacy of RTS,S\/AS01E in Plasmodium falciparum-exposed Kenyan adults treated with antimalarial chemopreventive drugs. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.01.10.25320353 (2025).","DOI":"10.1101\/2025.01.10.25320353"},{"key":"3739_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","volume":"22","author":"MS Sissoko","year":"2022","unstructured":"Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. 22, 377\u2013389 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"3739_CR42","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","volume":"27","author":"M Oneko","year":"2021","unstructured":"Oneko, M. et al. Safety, immunogenicity and efficacy of PfSPZ vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat. Med. 27, 1636\u20131645 (2021).","journal-title":"Nat. Med."},{"key":"3739_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4269\/ajtmh.2012.10-0658","volume":"86","author":"SC Murphy","year":"2012","unstructured":"Murphy, S. C. et al. Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am. J. Trop. Med. Hyg. 86, 383\u2013394 (2012).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3739_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04239-x","volume":"21","author":"DEB Hergott","year":"2022","unstructured":"Hergott, D. E. B. et al. Feasibility of community at-home dried blood spot collection combined with pooled reverse transcription PCR as a viable and convenient method for malaria epidemiology studies. Malar. J. 21, 221 (2022).","journal-title":"Malar. J."},{"key":"3739_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03907-8","volume":"20","author":"M Chang","year":"2021","unstructured":"Chang, M., Johnston, S., Seilie, A. M., Hergott, D. & Murphy, S. C. Application of dried blood spot sample pooling strategies for Plasmodium 18S rRNA biomarker testing to facilitate identification of infected persons in large-scale epidemiological studies. Malar. J. 20, 391 (2021).","journal-title":"Malar. J."},{"key":"3739_CR46","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733\u2013744.e8 (2020).","journal-title":"Immunity"},{"key":"3739_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2203067","volume":"387","author":"RL Wu","year":"2022","unstructured":"Wu, R. L. et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N. Engl. J. Med. 387, 397\u2013407 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3739_CR48","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41591-020-1084-0","volume":"26","author":"CM Andrade","year":"2020","unstructured":"Andrade, C. M. et al. Increased circulation time of Plasmodium falciparum underlies persistent asymptomatic infection in the dry season. Nat. Med. 26, 1929\u20131940 (2020).","journal-title":"Nat. Med."},{"key":"3739_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1086\/430707","volume":"41","author":"DA Diallo","year":"2005","unstructured":"Diallo, D. A. et al. Community permission for medical research in developing countries. Clin. Infect. Dis. 41, 255\u2013259 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"3739_CR50","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1128\/JCM.02549-12","volume":"50","author":"SC Murphy","year":"2012","unstructured":"Murphy, S. C., Daza, G., Chang, M. & Coombs, R. Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing. J. Clin. Microbiol. 50, 4128\u20134130 (2012).","journal-title":"J. Clin. Microbiol."},{"key":"3739_CR51","unstructured":"MalariaGEN. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples. Wellcome Open Res. 8, 22 (2023)."},{"key":"3739_CR52","doi-asserted-by":"publisher","unstructured":"Miles, A. et al. cggh\/scikit-allel: v1.3.13. Zenodo https:\/\/doi.org\/10.5281\/zenodo.13772087 (2024).","DOI":"10.5281\/zenodo.13772087"},{"key":"3739_CR53","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1111\/1755-0998.13622","volume":"22","author":"E LaVerriere","year":"2022","unstructured":"LaVerriere, E. et al. Design and implementation of multiplexed amplicon sequencing panels to serve genomic epidemiology of infectious disease: a malaria case study. Mol. Ecol. Resour. 22, 2285\u20132303 (2022).","journal-title":"Mol. Ecol. Resour."},{"key":"3739_CR54","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581\u2013583 (2016).","journal-title":"Nat. Methods"},{"key":"3739_CR55","unstructured":"Wickham, H. stringr: simple, consistent wrappers for common string operations. R package version 1.5.1 https:\/\/cran.r-project.org\/web\/packages\/stringr\/index.html (2023)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03739-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03739-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03739-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:24:06Z","timestamp":1757179446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03739-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3739"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03739-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.S. has filed patent PCT\/US2018\/017826 describing the CIS43 antibody. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}